论文部分内容阅读
目的探究持续静脉泵入呋塞米与多巴胺联合参麦注射液治疗难治性心力衰竭患者利尿剂抵抗的临床效果。方法选取我院于2014年10月至2016年9月收治的伴利尿剂抵抗的难治性心力衰竭患者98例,随机分为对照组与研究组,每组各49例,对照组给予常规的抗心力衰竭及利尿剂进行治疗,研究组在对照组的基础上进行持续静脉泵入呋塞米与多巴胺,同时结合静脉滴注参麦注射液进行治疗,观察比较两组患者的治疗效果。结果通过比较两组患者临床治疗总有效率,研究组为93.9%,明显高于对照组的79.6%,且差异具有显著性(P<0.05)。观察两组患者左心室射血分数(LVEF)、每搏输出量(SV)、心脏指数(CI)、心率(HR),研究组改善程度优于对照组,其差异具有统计学意义(P<0.05)。研究组不良反应发生率与对照组无显著性差异(P>0.05)。结论治疗伴利尿剂抵抗的难治性心力衰竭患者,采用持续静脉泵入呋塞米与多巴胺联合参麦注射液有较好的治疗效果,对心功能具有显著的改善作用,安全性较好,值得临床推广应用。
Objective To investigate the clinical effect of continuous intravenous infusion of furosemide and dopamine combined with Shenmai injection on diuretic resistance in patients with refractory heart failure. Methods A total of 98 patients with refractory heart failure with diuretic resistance who were treated in our hospital from October 2014 to September 2016 were randomly divided into control group and study group, 49 cases in each group. The control group was given conventional Heart failure and diuretics. The study group was given continuous intravenous furosemide and dopamine on the basis of the control group, meanwhile treated with intravenous infusion of Shenmai injection. The therapeutic effect was observed and compared between the two groups. Results By comparing the total effective rate of two groups of patients, the study group was 93.9%, significantly higher than 79.6% of the control group, and the difference was significant (P <0.05). The left ventricular ejection fraction (LVEF), stroke volume (SV), cardiac index (CI) and heart rate (HR) of the two groups were observed. The improvement in the study group was better than that in the control group (P < 0.05). The incidence of adverse reactions in the study group and the control group no significant difference (P> 0.05). Conclusions The treatment of refractory heart failure with diuretic resistance in patients with continuous intravenous furosemide and dopamine combined with shenmai injection has a better therapeutic effect on cardiac function has a significant improvement in the role of safety is better, Worthy of clinical application.